pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ryanodex
drug · small molecule
save

dantrolene sodium

Phase 2updated 3mo ago
by Washington University in St Louis🔗 ChEMBL
Phase 2
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

Ryanodine receptor 3Ryanodine receptor 1

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand
Ryanodex
trade names
Agilus, Dantrium, Dantrolene sodium, Revonto, Ryanodex
generic
dantrolene sodium
MOA
Ryanodine receptor 3 antagonist; Ryanodine receptor 1 antagonist
indication
Malignant Hyperthermia
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?